Tag: Daridorexant

While insomnia affects 30–50% of people short-term, with chronic cases impacting 5–10% of the population, medications like zopiclone have fallen out of favor due to dependency risks and side effects. This has led to the development of new, targeted drug classes, presenting an important new alternative to zopiclone for patients seeking safer, more effective sleep solutions.

Approximately 30% to 40% of adults in the U.S. report symptoms of insomnia each year. In response, pharmacology has evolved, leading to a key question for many: **What is the new class of drugs for insomnia?** The answer lies in Dual Orexin Receptor Antagonists (DORAs), which offer a novel approach to treatment.

Chronic insomnia disorder affects an estimated 10% of the adult population, leading many to seek medication [1.7.3]. For those prescribed the medication, a common question is: **what does Quviviq feel like?** This article explores the range of experiences.

In the past decade, a new class of sleeping pills known as orexin receptor antagonists has emerged, offering a different approach to insomnia treatment compared to traditional sedative-hypnotics like Ambien. **What is the new pill like Ambien**, and how do these newer drugs function differently to promote sleep?

According to the National Sleep Foundation, as many as 50% of older adults experience difficulty initiating or maintaining sleep. Historically, older sleep medications posed significant risks for this population, but a newer class of drugs has emerged. So, what is the new sleeping pill for the elderly? Newer medications called dual orexin receptor antagonists (DORAs) are offering a safer, more targeted approach to treating insomnia in older adults.

Chronic insomnia affects up to 12% of the adult population in Switzerland, with significant impacts on both physical and mental health. A modern treatment developed by Swiss biopharmaceutical company Idorsia, known as the 'Swiss sleep pill,' is QUVIVIQ (daridorexant), a dual orexin receptor antagonist (DORA) that works differently than traditional sedatives by targeting the brain's wakefulness system.